- Home
- VCTR vs ACAD Comparison
VCTR vs ACAD Comparison
Compare VCTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCTR
- ACAD
- Stock Information
- Founded
- VCTR 2013
- ACAD 1993
- Country
- VCTR United States
- ACAD United States
- Employees
- VCTR 460
- ACAD N/A
- Industry
- VCTR Investment Managers
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- VCTR Finance
- ACAD Health Care
- Exchange
- VCTR Nasdaq
- ACAD Nasdaq
- Market Cap
- VCTR 4.8B
- ACAD 4.0B
- IPO Year
- VCTR 2018
- ACAD 2004
- Fundamental
- Price
- VCTR $71.28
- ACAD $25.99
- Analyst Decision
- VCTR Buy
- ACAD Buy
- Analyst Count
- VCTR 10
- ACAD 20
- Target Price
- VCTR $72.30
- ACAD $28.63
- AVG Volume (30 Days)
- VCTR 631.6K
- ACAD 2.0M
- Earning Date
- VCTR 08-07-2025
- ACAD 08-06-2025
- Dividend Yield
- VCTR 2.75%
- ACAD N/A
- EPS Growth
- VCTR 12.49
- ACAD 615.00
- EPS
- VCTR 4.00
- ACAD 1.33
- Revenue
- VCTR $1,028,813,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- VCTR $47.18
- ACAD $14.01
- Revenue Next Year
- VCTR $15.21
- ACAD $11.72
- P/E Ratio
- VCTR $17.81
- ACAD $19.61
- Revenue Growth
- VCTR 20.90
- ACAD 14.41
- 52 Week Low
- VCTR $47.00
- ACAD $13.40
- 52 Week High
- VCTR $73.42
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- VCTR 56.16
- ACAD 62.55
- Support Level
- VCTR $70.88
- ACAD $25.14
- Resistance Level
- VCTR $72.13
- ACAD $26.65
- Average True Range (ATR)
- VCTR 1.26
- ACAD 0.67
- MACD
- VCTR -0.12
- ACAD 0.04
- Stochastic Oscillator
- VCTR 58.68
- ACAD 70.27
About VCTR Victory Capital Holdings Inc.
Victory Capital Holdings Inc is an independent investment management firm. The company operates its business through franchises and solutions platform. It provides centralized distribution, marketing, and operations infrastructure to the company's franchises and solutions platform. The company operates through one business segment that is Investment management services and products to institutional, intermediary, retirement platforms, and individual investors. The franchises and solutions platform manages a variety of investment strategies for its customers. It derives majority of its revenues from asset-based fees from investment management products and services to individuals and institutions.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.